V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization.

A recent study by a team from Chiba University has demonstrated a promising approach for fighting antibiotic resistance by identifying a compound, V-161, that inhibits a sodium-pumping enzyme critical ...

MRSA was once eradicated reliably by vancomycin (Vancocin AE), an antibiotic of the glycopeptide class. With time, the MRSA bacteria became resistant to vancomycin and vancomycin-resistant ...

The major objective of this research collaboration is to develop new therapeutic drug candidates which target antimicrobial resistant pathogens. This work will utilize the Immuron technology platform, ...

There were no drug-related treatment withdrawals or no drug-related serious adverse events, or other safety findings of concern. In the phase 2b vancomycin control arm, 14 out of 14 patients ...

Conjunctival bacteria showed increased resistance to fluoroquinolones, particularly coagulase-negative Staphylococcus species, necessitating cautious antibiotic use. Vancomycin and third-generation ...

1 Department of Fibre and Polymer Technology, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden 2 Department of Materials, ...

Imagine that the next time you catch a stomach bug and antibiotics fail to work, you knock back a vial of clear liquid. The solution teems with bacteriophages, viruses resembling tiny rocket ships.

The growth of the vancomycin market is driven by several key factors, including the increasing prevalence of antibiotic-resistant infections, advancements in pharmaceutical manufacturing ...